Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

0
4

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

from News Medical Medical Research News Feed https://ift.tt/3uxHUJI https://ift.tt/eA8V8J

Written by
This news first appeared on https://techncruncher.blogspot.com/2021/10/osimertinib-offers-hint-of-added.html under the title “Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy”. Bolchha Nepal is not responsible or affiliated towards the opinion expressed in this news article.